| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/28/2011 | US20110097343 Diagnosis and therapy of hematological malignancies |
| 04/28/2011 | US20110097335 Abc transporter protein expression inhibitor |
| 04/28/2011 | US20110097334 Novel Marker Genes for Regulatory T Cells from Human Blood |
| 04/28/2011 | US20110097333 Therapeutic and diagnostic agents |
| 04/28/2011 | US20110097328 Methods and compositions for increasing the activity of inhibitory rna |
| 04/28/2011 | US20110097325 Modulation of T cell Differentiation for the treatment of T helper cell mediated diseases |
| 04/28/2011 | US20110097324 Compositions and methods for modulating nicotinic/nmda receptor function |
| 04/28/2011 | US20110097321 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| 04/28/2011 | US20110097320 4-aminoquinazoline derivatives and methods of use thereof |
| 04/28/2011 | US20110097315 Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer |
| 04/28/2011 | US20110097309 Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue |
| 04/28/2011 | US20110097306 Oral formulations of cladribine |
| 04/28/2011 | US20110097305 Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors |
| 04/28/2011 | US20110097303 Methods and compositions for treating and preventing viral infections |
| 04/28/2011 | US20110097299 Swellable and degradable microspheres |
| 04/28/2011 | US20110097282 New Use For Budesonide and Formoterol |
| 04/28/2011 | US20110097280 Intracorporeal Medicaments for Photodynamic Treatment of Disease |
| 04/28/2011 | US20110097261 Amigo-2-inhibitors for treating, diagnosing or detecting cancer |
| 04/28/2011 | DE202010016398U1 Verbesserungen bei pharmazeutischen Zusammensetzungen und bezüglich pharmazeutischer Zusammensetzungen With respect to improvements in pharmaceutical compositions and pharmaceutical compositions |
| 04/28/2011 | DE102009050854A1 Verwendung von Menthylethern als antibakterielle, antimycotische oder antivirale Wirkstoffe Use of Menthylethern as antibacterial, antifungal, or antiviral agents |
| 04/28/2011 | DE102009049551A1 Use of the active substance propyphenazone for the therapeutic treatment of tumor, where the active substance inhibits the growth of tumor cells and/or degenerates the tumor cells |
| 04/28/2011 | DE102009049211A1 Sulfoxide Sulfoxides |
| 04/28/2011 | DE102009043260A1 Pyridinyl-imidazolonderivate Pyridinyl-imidazolone derivatives |
| 04/28/2011 | DE102006031813B4 Verwendung basischer Acetophenone als Hemmstoffe von NO-Synthasen Using basic acetophenones as inhibitors of NO synthases |
| 04/28/2011 | CA2815437A1 Triptans for the treatment of psoriasis |
| 04/28/2011 | CA2814958A1 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent |
| 04/28/2011 | CA2793835A1 Methods and compositions for cell-proliferation-related disorders |
| 04/28/2011 | CA2781525A1 Coated capsules and tablets of a fatty acid oil mixture |
| 04/28/2011 | CA2781499A1 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease |
| 04/28/2011 | CA2780533A1 5-hydroxypyrimidine-4-carboxamide derivative |
| 04/28/2011 | CA2779309A1 Method for treating androgen receptor positive cancers |
| 04/28/2011 | CA2779298A1 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| 04/28/2011 | CA2779292A1 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| 04/28/2011 | CA2779282A1 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
| 04/28/2011 | CA2779233A1 Combination cancer therapy with hsp90 inhibitory compounds |
| 04/28/2011 | CA2778695A1 Methods and compositions for enhancing polypeptide production |
| 04/28/2011 | CA2778613A1 Methods and compositions for panic disorders |
| 04/28/2011 | CA2778611A1 Coumarin compounds as receptor modulators with therapeutic utility |
| 04/28/2011 | CA2778504A1 Methods of using macrocyclic inhibitors of serine protease enzymes |
| 04/28/2011 | CA2778493A1 Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
| 04/28/2011 | CA2778484A1 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| 04/28/2011 | CA2778483A1 Modulation of axon degeneration |
| 04/28/2011 | CA2778472A1 Compositions and methods for controlling pupil dilation comprising phentolamine |
| 04/28/2011 | CA2778441A1 Methods of making and using compositions comprising flavonoids |
| 04/28/2011 | CA2778423A1 Alpha adrenergic receptor modulators |
| 04/28/2011 | CA2778411A1 Pharmaceutical composition for oral administration |
| 04/28/2011 | CA2778384A1 Glycoside derivative and uses thereof |
| 04/28/2011 | CA2778350A1 Therapeutic composition |
| 04/28/2011 | CA2778349A1 Novel compositions for preventing and/or treating lysosomal storage disorders |
| 04/28/2011 | CA2778348A1 Novel compositions for preventing and/or treating degenerative disorders of the central nervous system |
| 04/28/2011 | CA2778340A1 Extracts, fractions and compositions comprising acetogenins and their applications |
| 04/28/2011 | CA2778291A1 Akt inhibitors |
| 04/28/2011 | CA2778279A1 Method and kit for gastro-intestinal cleansing |
| 04/28/2011 | CA2778256A1 Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis |
| 04/28/2011 | CA2778194A1 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives |
| 04/28/2011 | CA2778182A1 Novel parasite therapy |
| 04/28/2011 | CA2778103A1 Donepezil-containing transdermal absorption formulation |
| 04/28/2011 | CA2778060A1 Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| 04/28/2011 | CA2778049A1 Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
| 04/28/2011 | CA2778009A1 Aqueous patches containing diclofenac sodium |
| 04/28/2011 | CA2777938A1 Method of preventing type 1 diabetes |
| 04/28/2011 | CA2777902A1 Compounds |
| 04/28/2011 | CA2777883A1 Medical utility of glycan-binding proteins and glycans |
| 04/28/2011 | CA2777881A1 Pyrazolopyrimidine derivatives |
| 04/28/2011 | CA2777824A1 Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| 04/28/2011 | CA2777551A1 Neuroprotection and myelin repair using nestorone |
| 04/28/2011 | CA2777489A1 Method for wetting a powder containing benzoyl peroxide |
| 04/28/2011 | CA2777430A1 Substituted benzosulphonamides |
| 04/28/2011 | CA2777310A1 Methods and systems for pharmacogenomic treatment of cardiovascular conditions |
| 04/28/2011 | CA2777304A1 Substituted benzosulphonamides |
| 04/28/2011 | CA2777245A1 Compositions for treatment of cystic fibrosis and other chronic diseases |
| 04/28/2011 | CA2777231A1 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
| 04/28/2011 | CA2777187A1 Process and compounds for the manufacture of oseltamivir and analogs thereof, and new antiviral agents |
| 04/28/2011 | CA2777071A1 Substituted halophenoxybenzamide derivatives |
| 04/28/2011 | CA2777019A1 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
| 04/28/2011 | CA2776914A1 Diazepan derivatives as modulators of chemokine receptors |
| 04/28/2011 | CA2776480A1 Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators |
| 04/28/2011 | CA2776407A1 Method of preparing sitagliptin and intermediates used therein |
| 04/28/2011 | CA2775806A1 Novel dosing regimen and method of treatment |
| 04/28/2011 | CA2775110A1 Orally transformable tablets |
| 04/28/2011 | CA2775009A1 Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
| 04/28/2011 | CA2774910A1 Novel acylpiperazinones and their use as pharmaceuticals |
| 04/28/2011 | CA2773210A1 Derivatives of n-hydroxybenzamide for treating hiv infections |
| 04/28/2011 | CA2772657A1 Compounds and compositions as tlr activity modulators |
| 04/28/2011 | CA2765748A1 Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof |
| 04/27/2011 | EP2315026A2 Taxol immunoassay |
| 04/27/2011 | EP2314716A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/27/2011 | EP2314709A1 Method for preparing reduced type coenzyme q10 |
| 04/27/2011 | EP2314700A1 Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| 04/27/2011 | EP2314693A2 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| 04/27/2011 | EP2314691A2 Fuctional and hyperfunctional siRNA |
| 04/27/2011 | EP2314689A2 Antisense compounds targeted to connexins and methods of use thereof |
| 04/27/2011 | EP2314627A2 Method for the treatment of multiple sclerosis |
| 04/27/2011 | EP2314595A2 Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
| 04/27/2011 | EP2314594A1 6-modified bicyclic nucleic acid analogs |
| 04/27/2011 | EP2314593A1 Platelet ADP receptor inhibitors |
| 04/27/2011 | EP2314591A1 Pseudopolymorphic forms of a hiv protease inhibitor |
| 04/27/2011 | EP2314590A1 Substituted quinolones and methods of use |
| 04/27/2011 | EP2314589A1 Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone |
| 04/27/2011 | EP2314588A1 Compounds of estrogen-related receptor modulators and the uses thereof |